Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript

Core Insights - The company is focusing on the development of next-generation HIV treatments, emphasizing strategic decisions made recently in this area [1] Group 1: HIV Treatment Development - The company is prioritizing the development of 6-month regimens, long-acting INSTI GS-3242, and bNAbs in combination with lenacapavir over other combinations in the pipeline based on data from CROI and other studies [1]